Asia Pac IPO & Placement Research, China biotech, Aequitas Research

Ke Yan, CFA, FRM

An inquisitive investment analyst with background in both finance and computing. Covering ECM research, biotech, market data analytics.

Asia Pac IPO & Placement Research, China biotech

IPOs and Placements coverage across Asia Pacific

Aequitas Research

We cover all listing across the Asia Pacific along with follow-up placements. As of Dec 2020, our team had covered 539 IPOs with a hit rate of 73.5% and 685 placements with a hit rate of 66.8%.

We combine fundamental bottom-up views with our proprietary quantitative framework to provide a holistic coverage across new listings and placements. Our coverage includes pre-IPO notes before the deal is launched, follow-up analysis once the deal is live and post-listing trading analysis as well.

Equity Capital Markets

<ul>
<li>Sirnaomics is a biotech with a focus on siRNA technology for oncology and fibrosis diseases, and is looking to raise up to USD 150m via a Hong Kong listing.</li>
<li>We look at the company's core products, including STP705 and STP707. Having looked at the company's products, we aren't convinced that they can be blockbuster drugs.</li>
<li>We think the company's product pipeline is too light. The company management lacks track record in siRNA development and investors are mostly domestic individuals and funds.</li>
</ul>


Sirnaomics is a biotech with a focus on siRNA technology for oncology and fibrosis diseases, and is looking to raise up to USD 150m via a Hong Kong listing.
We look at the company's core products, including STP705 and STP707. Having looked at the company's products, we aren't convinced that they can be blockbuster drugs.
We think the company's product pipeline is too light. The company management lacks track record in siRNA development and investors are mostly domestic individuals and funds.


Sirnaomics Pre-IPO: Not a Convincing siRNA Pipeline